Insights about ADCs from AACR 2024

As AACR 2024 concluded, we witnessed exciting breakthroughs in the field of antibody-drug conjugates (ADCs). Notably, bispecific antibody-drug conjugates (BsADCs) emerged as a focal point of attention. We are pleased to share some of the noteworthy therapies presented at the conference:

Selected Research Highlights:

- Innovent IBI3001: A potentially first-in-class bispecific ADC against B7-H3 and Her2 that is site-specifically glycan-conjugate for multiple solid tumors. IBI3001 showed strong anti-tumor efficacy in vitro and in vivo across multiple solid tumors and is well tolerated.

- Innovent IBI334: A novel ADCC-enhanced B7-H3/Her2 bispecific antibody, which showed better tumor growth inhibition in vitro and in vivo than Her2 monoclonal antibody and c-met/Her2 bispecific antibody benchmarks.

- Alphamab JSKN003-101: An anti-HER2 bispecific ADC for the treatment of HER2-expressing advanced solid tumors. According to data, JSKN003 exhibited a favorable tolerability, and safety profile and encouraged preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors.

ADC target proteins from ACROBiosystems (partial)

We provide a wide range of solutions to support ADC development. Download our ebook to discover ADC development reagents that can assist you in your ADC development journey:

Download the eBook

>>>Explore more ADC core reagents now!